Chrysalis, a rentable cleanroom provider, has formally announced its entry into the market after acquiring facility assets from Azzur Group’s bankruptcy.
The new GMP-ready cleanroom space and service provider is calling this a strategic ownership investment to fuel future expansion.
When Azzur went bankrupt in March this year, after accumulating $100m in debt, the company sold its consulting arm to ELIQUENT Life Sciences, with the support of an investor, for $56m. However, the “Cleanrooms On Demand” or “COD” arm was still left to be dealt with.
Azzur owned COD facilities in North Carolina, Massachusetts, and California. Headquartered in the US, Chrysalis will now operate facilities in Massachusetts and North Carolina.
The new GMP-ready cleanroom space and service provider is calling this a strategic ownership investment to fuel future expansion
The two facilities are both key biopharma hubs, offering flexible, GMP-compliant cleanroom environments and operational support to life sciences and biopharma companies.
The company’s services are designed to help innovators accelerate the development of novel therapies by providing rapid, scalable access to manufacturing capacity without the long lead times or fixed overheads typically associated with facility build-outs.
What is Chrysalis’ business model?
The firm’s business model enables clients to take only the space and services they require, with entry to cleanroom environments available in as little as four to six weeks.
This agility allows life sciences companies to align manufacturing activities closely with project milestones, maintaining programme control while containing costs.
Commenting on the launch, Sarah Stevens, CEO of Chrysalis, said: “Our model is particularly valuable for programmes where retaining process control, protecting intellectual property, and minimising risk are crucial considerations.
“By providing rapid access to GMP-compliant space and operational support, we empower our customers to advance on their own terms, transforming scientific promise into real progress without the burden of scheduling constraints or unnecessary ongoing expense.”
The two facilities are both key biopharma hubs
Chrysalis partners with a broad range of clients across the life sciences ecosystem from early-stage biotech firms to top 10 global pharmaceutical companies, contract research organisations (CROs), and other sector stakeholders.
Its facilities are designed to accommodate diverse therapeutic modalities and technical requirements, offering cleanroom environments tailored to each client’s operational and regulatory needs.
Stevens added: “Whether clients are navigating early development or preparing for commercialisation, we’re here to grow with them. We don’t just provide space — we build partnerships grounded in collaborative operational excellence and a deep understanding of what it takes to operate in a GMP environment.”
Looking ahead, Chrysalis is positioned to scale quickly, with plans to expand its infrastructure, extend its service offering, and enter additional geographies to meet the increasing demand for agile, flexible manufacturing solutions in the biopharmaceutical sector.
